Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 6/20 | 0.40 |
| ▸ | GRB2 | P62993 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.34 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 2/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14940740 | 0.91 | ENPEP (0.40) | ENPEPCTSDL3MBTL1AKR1B1 | |
| SCHEMBL10982903 | 0.91 | ENPEP (0.40) | ENPEPCTSDL3MBTL1AKR1B1 | |
| SCHEMBL10982907 | 0.91 | ENPEP (0.40) | ENPEPCTSDL3MBTL1AKR1B1 | |
| SCHEMBL31643061 | 0.86 | CTSD (0.42) | ENPEPCTSDAKR1B1 | |
| SCHEMBL30799829 | 0.84 | GHSR (0.37) | — | |
| SCHEMBL24270549 | 0.82 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL14065661 | 0.82 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL8437180 | 0.81 | MME (0.37) | AKR1B1 | |
| SCHEMBL8437182 | 0.81 | MME (0.37) | AKR1B1 | |
| SCHEMBL31618959 | 0.81 | ACE (0.51) | CTSDACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | ENPEP 41/4885GRB2 600/4885CTSD 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.